News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
413,264 Results
Type
Article (33195)
Company Profile (64)
Press Release (380002)
Multimedia
Podcasts (75)
Webinars (7)
Section
Business (113305)
Career Advice (1334)
Deals (24182)
Drug Delivery (108)
Drug Development (60047)
Employer Resources (105)
FDA (10228)
Job Trends (9134)
News (212768)
Policy (25742)
Tag
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (1848)
Accelerated approval (29)
Adcomms (26)
Allergies (108)
Alliances (42405)
ALS (119)
Alzheimer's disease (1342)
Antibody-drug conjugate (ADC) (247)
Approvals (10363)
Artificial intelligence (338)
Autoimmune disease (99)
Automation (21)
Bankruptcy (238)
Best Places to Work (7693)
BIOSECURE Act (16)
Biosimilars (153)
Biotechnology (42)
Bladder cancer (113)
Brain cancer (57)
Breast cancer (433)
Cancer (3536)
Cardiovascular disease (283)
Career advice (1139)
Career pathing (23)
CAR-T (191)
CDC (53)
Cell therapy (521)
Cervical cancer (26)
Clinical research (50880)
Collaboration (1407)
Company closure (3)
Compensation (970)
Complete response letters (54)
COVID-19 (2595)
CRISPR (62)
C-suite (400)
Cystic fibrosis (87)
Data (4397)
Decentralized trials (1)
Denatured (12)
Depression (102)
Diabetes (387)
Diagnostics (3734)
Digital health (23)
Diversity (8)
Diversity, equity & inclusion (34)
Drug discovery (177)
Drug pricing (176)
Drug shortages (31)
Duchenne muscular dystrophy (191)
Earnings (42779)
Editorial (53)
Employer branding (13)
Employer resources (98)
Events (48358)
Executive appointments (437)
FDA (12463)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (8)
Frontotemporal dementia (17)
Funding (929)
Gene editing (138)
Generative AI (32)
Gene therapy (460)
GLP-1 (938)
Government (4367)
Grass and pollen (6)
Guidances (303)
Healthcare (11436)
HIV (49)
Huntington's disease (39)
IgA nephropathy (63)
Immunology and inflammation (182)
Immuno-oncology (44)
Indications (73)
Infectious disease (2848)
Inflammatory bowel disease (116)
Inflation Reduction Act (11)
Influenza (109)
Intellectual property (158)
Interviews (233)
IPO (10551)
IRA (46)
Job creations (1756)
Job search strategy (959)
JPM (44)
Kidney cancer (10)
Labor market (48)
Layoffs (338)
Leadership (20)
Legal (7099)
Liver cancer (68)
Longevity (14)
Lung cancer (493)
Lymphoma (286)
Machine learning (32)
Management (33)
Manufacturing (561)
MASH (136)
Medical device (6067)
Medtech (6091)
Mergers & acquisitions (14483)
Metabolic disorders (1076)
Multiple sclerosis (109)
NASH (20)
Neurodegenerative disease (236)
Neuropsychiatric disorders (70)
Neuroscience (2238)
Neurotech (1)
NextGen: Class of 2026 (3663)
Non-profit (2791)
Now hiring (9)
Obesity (554)
Opinion (239)
Ovarian cancer (108)
Pain (118)
Pancreatic cancer (179)
Parkinson's disease (214)
Partnered (24)
Patents (312)
Patient recruitment (291)
Peanut (43)
People (25703)
Pharmaceutical (20)
Pharmacy benefit managers (20)
Phase 1 (15370)
Phase 2 (22100)
Phase 3 (17931)
Pipeline (3839)
Policy (271)
Postmarket research (1846)
Preclinical (6387)
Press Release (28)
Prostate cancer (174)
Psychedelics (42)
Radiopharmaceuticals (231)
Rare diseases (640)
Real estate (2609)
Recruiting (47)
Regulatory (17893)
Reports (24)
Research institute (1630)
Resumes & cover letters (196)
Rett syndrome (26)
RNA editing (9)
RSV (80)
Schizophrenia (120)
Series A (128)
Series B (102)
Service/supplier (3)
Sickle cell disease (61)
Special edition (11)
Spinal muscular atrophy (147)
Sponsored (27)
Startups (1913)
State (1)
Stomach cancer (13)
Supply chain (79)
Tariffs (71)
The Weekly (62)
Vaccines (1015)
Venture capital (61)
Weight loss (384)
Women's health (53)
Worklife (11)
Date
Last 7 days (369)
Last 30 days (1332)
Last 365 days (19603)
2026 (1766)
2025 (19916)
2024 (22360)
2023 (25259)
2022 (33391)
2021 (35894)
2020 (34073)
2019 (27913)
2018 (21257)
2017 (20208)
2016 (18705)
2015 (21497)
2014 (15954)
2013 (12877)
2012 (13625)
2011 (14402)
2010 (13079)
Location
Africa (583)
Alabama (50)
Alaska (3)
Arizona (124)
Arkansas (5)
Asia (26973)
Australia (4837)
California (6791)
Canada (2025)
China (782)
Colorado (272)
Connecticut (304)
Delaware (239)
Europe (64776)
Florida (1027)
Georgia (217)
Hawaii (4)
Idaho (30)
Illinois (485)
India (47)
Indiana (330)
Iowa (17)
Japan (338)
Kansas (76)
Kentucky (24)
Louisiana (17)
Maine (32)
Maryland (971)
Massachusetts (4813)
Michigan (163)
Minnesota (240)
Mississippi (1)
Missouri (77)
Montana (21)
Nebraska (11)
Nevada (73)
New Hampshire (27)
New Jersey (2040)
New Mexico (15)
New York (1935)
North Carolina (810)
North Dakota (5)
Northern California (3391)
Ohio (189)
Oklahoma (9)
Oregon (14)
Pennsylvania (1364)
Puerto Rico (12)
Rhode Island (17)
South America (806)
South Carolina (32)
South Dakota (1)
Southern California (2630)
Tennessee (85)
Texas (876)
United States (23982)
Utah (158)
Vermont (1)
Virginia (170)
Washington D.C. (43)
Washington State (527)
West Virginia (2)
Wisconsin (60)
Wyoming (2)
413,264 Results for "morphosys ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Business
MorphoSys AG Reports First Quarter 2024 Financial Results
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
April 29, 2024
·
18 min read
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Business
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
March 13, 2024
·
22 min read
Press Releases
Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union
December 18, 2025
·
3 min read
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
February 5, 2026
·
7 min read
Business
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
November 15, 2023
·
15 min read
Startups
Six Startups Changing The Way We Age
Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.
July 9, 2025
·
11 min read
·
Tristan Manalac
Press Releases
Tenacia Biopharmaceuticals and Golden Age Health Partner to Commercialize ZTALMY® for CDKL5 Deficiency Disorder in Mainland China
February 2, 2026
·
3 min read
1 of 41,327
Next
